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Abstract 
Despite national guidelines, the evaluation of effects of primary systemic treatment (PST) in 
breast cancer is a complex challenge. Our aims were to evaluate the response patterns 
focusing on correlations of radiological and pathological tumor size, regression heterogeneity 
in different molecular subtypes, cellularity changes and the incidence of enlarged, 
multinucleated neoplastic cells related to therapy. 
Slides of pretreatment biopsies and resection specimens of consecutive cases were reevaluated 
focusing on heterogeneity of regression per whole slide, and 40x or 100x magnification fields. 
Alteration in cellularity and the presence of multinucleated tumor giant cells were noted. The 
correlation of pathological and radiological sizes and their alterations were analyzed by Spearman rank 
correlation. 
The present study included 106 tumors. A decrease in size (84.9%) and cellularity (76.4%) was noted 
in all molecular subtypes. Inhomogeneous regression was found in 45.3%, with minor inhomogeneity 
in the majority. Scatter pattern regression was seen only in 8 cases (7.5%). Significant correlations 
were found between the pathological and radiological sizes (p=0.02), and between the alterations of 
cellularity and pathological and radiological size (p=0.04; p=0.03, respectively). Multinucleated tumor 
giant cells were noted in 17.9% (n=19), nearly exclusively in cases treated with PST including 
taxanes. 
Regression inhomogeneity following PST is present in about half of the cases, and is not 
related to molecular subtypes. The evaluation of the maximum area of the tumor bed is 
recommended for the proper evaluation of regression. Multinucleated tumor giant cells are 
related to PST including taxane derivate, and may cause upgrading. 
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A 40-year-old woman with a cT2(34 mm)N0M0 grade 3 estrogen receptor (ER) 
positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer of no 
special type (Fig. 1A) received 6 cycles of docetaxel, epirubicin and cyclophosphamide as 
primary systemic treatment (PST), showed substantial regression on imaging, and underwent 
breast conserving surgery with sentinel node biopsy. The localization metal clip was not 
included in the first excision and a re-excision was needed to remove the clip, too. The first 
surgical specimen included an empty tumor bed area with 11.4 mm greatest dimension, but 
the empty tumor bed was in the margin (Fig. 1B). The second specimen sent for histology 
also included the localization clip and a tumor bed area harboring both ductal carcinoma in 
situ and a 6 mm-large residual grade 3 invasive carcinoma (ypT1b) (Fig. 1C and 1D). The 
cited introductory example highlights that tumor regression may be misleadingly 
inhomogeneous, and this may lead to the false impression of complete regression on one end 
and lack of regression on the other end of the spectrum unless the full tumor bed is 
investigated. 
PST of breast cancer has become more frequent recently. This approach to systemic 
treatment is currently applied in bulky (>2cm) tumors or locally advanced cancers [1]. The 
radiologic and pathologic interpretation of regression is sometimes controversial due to some 
mismatch between the entities used for assessment. There is no internationally agreed 
consensus on how different imaging modalities should be priorized and specimen handling is 
also rather heterogeneous. 
The presence or absence of regression is evaluated by radiologic modalities, namely 
ultrasonography (US), mammography and magnetic resonance imaging (MRI). This 
examination influences the continuation, shift or termination of PST and the multidisciplinary 
decision about surgical treatment. After the operation, the pathological examination reveals 
the degree of regression: pathological complete regression (pCR) on one end, and the 
complete lack of regression on the other end of the spectrum. The scale of regression affects 
further treatment decisions. Therefore, a standard approach to the evaluation of the breast 
specimen is crucial. To reach this aim, national guidelines have been developed in individual 
countries like Australia [2], Belgium [3], Germany [4], the United Kingdom [5], the 
Netherlands [6], the United States [7] and Hungary [8]. 
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Despite these guidelines or reviews [9; 10] aiming at some uniformity in breast cancer 
reporting, there are several inconsistencies, namely in specimen work-up, definition of pCR, 
patterns and grades of regression. 
After PST, the identification of the tumor bed may be difficult because the tumor may 
have become less firm, and less well circumscribed. Therefore, gross examination must be 
correlated with the clinical and especially radiological localization to ensure that the correct 
area is sampled. Systematic sampling should include the grossly visible tumor bed or the 
location of clip markers and neighboring areas to incorporate the area involved by carcinoma 
before treatment [10]. Digital photos, specimen mammography images or drawings should be 
taken for helping the comparison between clinical and morphological findings. 
Histopathological evaluation is based on sampling: representative areas are chosen for tissue 
blocks during grossing, and a tissue section represents about one thousandth of the whole 
thickness of the tissue block. It is obvious, that the more thorough the sampling, the more 
details one can discover under the microscope, especially in non-homogeneous lesions 
exemplified in the first paragraph and Figure 1. 
In case of inhomogeneous, scattered focal regression, the assessment of tumor size 
may be problematic, as well. The dimension of the largest invasive focus may deviate from 
the largest dimension of the residual tumor affected area in the tumor bed (i.e. the extent) 
[11]. 
According to the United States’ Food and Drug Administration (FDA), ‘Pathological 
complete response is defined as the absence of residual invasive cancer (ypT0ypN0 or 
ypT0isypN0) on evaluation of the complete resected breast specimen and all sampled regional 
lymph nodes following completion of neoadjuvant systemic therapy’ [12].The AJCC has 
endorsed the same definition [13]. This recommendation is based on the findings of the 
Collaborative Trials in Neoadjuvant Breast Cancer project. In this study, there was no 
difference in event-free and overall survival of patients having ypT0ypN0 or ypTisypN0 
breast cancer [14]. On the contrary, the German and Austrian Breast Groups demonstrated 
significant worsening in event-free survival of ypTisypN0 versus ypT0ypN0 breast cancer 
cases [15]. Therefore, an alternative definition of complete response was proposed by this 
group, which excludes both residual ductal carcinoma in situ (DCIS) and invasive carcinoma 
in the breast (ypT0ypN0 only). 
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Regression and its scale can be characterized by different parameters, like the size of 
residual invasive carcinoma, lymph node status, tumor cellularity, tumor grade, proportion of 
tumor remaining in breast (%) and finally the size of tumor bed in two dimensions. Several 
regression grading systems based on these parameters have been introduced and validated, 
including those described by Miller and Payne [16], Pinder [17], Denkert and Sinn [18] and 
Sataloff [19]. 
Another feature of response to neoadjuvant therapy is homogeneity or heterogeneity of 
the regression. According to Provenzano and coworkers, the patterns of residual disease are 
the following: homogenous regression (cellularity decreased, size unchanged), 
inhomogeneous regression (cellularity decreased, size variable, small areas without residual 
disease), "scatter pattern" (cellularity decreased, size variable, tumor bed slides without 
residual disease) and "concentric shrinkage" (CS) (size decreased, cellularity similar) [10]. 
Especially the "scatter pattern" may lead to diagnostic pitfalls if not systematically sampled. 
Not only the size and cellularity change following PST, but grade may also be altered. 
After PST, bizarre and/or macronucleated neoplastic giant cells may sometimes be found in 
the tumor bed. These cells are generally attributed to the effects of chemotherapy. The 
presence of these bizarre cells may increase the posttreatment grade, whereas a reduction in 
the proliferating cells may decrease it. 
The aims of the present study were to evaluate the response patterns in breast cancers 
after PST, focusing on correlations of radiological and pathological tumor sizes, regression 
heterogeneity in the tumor bed and in the axilla in different molecular subtypes of breast 
cancer, cellularity changes between biopsy and resection specimen, correlation between 
cellularity and size alterations and the incidence of macronucleated, bizarre neoplastic cells 
related to therapy. 
 
Materials and methods 
Consecutive invasive breast carcinomas treated with PST and operated on at the Bács-
Kiskun County Teaching Hospital, Kecskemét or at the Department of Surgery, University of 
Szeged from 2015 through February 2018 and from 2013 through May 2018, respectively 
were included. Additionally some earlier cases (from between 2010-2014) collected for a 
7 
 
previous study on PST (n=8) were also included. Exclusion criteria were unavailability of 
slides of either the biopsy or the excision specimen and primary endocrine therapy. 
Clinical data, namely age, gender, laterality, type of surgery, pre- and posttreatment 
size determined by US, mammography and MRI (as available), primary systemic therapy 
were collected from medical charts. Pathological data including ER, progesterone receptor 
(PR) and HER-2 status, ypT and ypN categories [13], TR and NR tumor and node regression 
categories [20], pre- and posttreatment histological grade, pathological size (both the largest 
invasive focus and extent of the area involved by tumor, either invasive or in situ) were 
obtained from the histopathology reports. The immunohistochemical surrogate classification 
of molecular subtypes of breast carcinomas was utilized according to the St. Gallen 
Consensus Conference [21]. The latest recommendations of American Society of Clinical 
Oncology were applied for the evaluation of HER-2 immunohistochemical staining [22]. 
Both departments have used the same work-up methodology recommended by the 3rd 
Hungarian Consensus Conference on Breast Cancer [8] including radiological localization, 
systematic sampling and clinical-pathological correlation on multidisciplinary meetings. 
All hematoxyline-eosin stained tumor (bed) containing slides of biopsy and excision 
specimens were analyzed. The cellularity was estimated by two pathologists (TZ & GC) both 
on biopsy and excision specimens. Consensus was always reached. 
The tumor bed areas showing complete regression or the absence of any regression 
pattern were evaluated on low (4x) and medium (10x) power fields (field areas: 0.24 mm2 and 
0.005 mm2, respectively). The presence of whole slides, any low power field or any medium 
power field showing complete response or the lack of any response were noted. Homogenous 
regression was defined as pCR (Fig.2A), absence of regression on all slides (Fig.2B) and 
uniform degree of regression on all slides (Fig.2C). Any other pattern was perceived as 
inhomogeneous response (Fig.2E-G). The latter included the so called "scatter pattern" [17], 
the CS [17], which was identified in case of reduction of tumor size with similar cellularity 
(Fig.2D).  
The cells having enlarged cytoplasm, multiple and/or enlarged bizarre hyperchromatic 
nuclei with different size and shape were labelled as “monster cells” for the purpose of this 
study (Fig.2H-I). 
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The slides of axillary sentinel lymph node excisions and/or axillary lymph node 
dissections were reevaluated and the presence or absence of metastasis and regression were 
documented. If metastatic nodes were seen with and without regression, inhomogeneous 
axillary response was identified. 
The alteration of pre- and posttreatment cellularity and size; and the correlation 
between radiological (exclusively uniformly available US data) and pathological size were 
analyzed by the Spearman rank model. All statistical tests were one-sided, and p<0.05 values were 
considered statistically significant. We utilized the SPSS Statistics software (IBM, SSPS 22.0, 
Armonk, NY USA). 
 
Results 
In this series, 106 cases were included: 56 and 50 patients from the University of 
Szeged and the Bács-Kiskun County Teaching Hospital, respectively. The basic clinical 
characteristics of these cases, namely age, type of surgery, histological type of tumor, ypT, 
ypN categories, pretreatment grade and therapy received are summarized in Table 1.Seven 
patients having stage IV disease defined by distant metastasis received palliative 
chemotherapy before surgery. 
The morphological parameters evaluated are displayed in Table 2. In all IHC 
approached molecular subtypes defined by the St. Gallen Consensus Conference in 2013, 
diminution was the most frequent size alteration after PST. The Spearman rank correlation 
revealed that the concordance between post-treatment pathological size and radiological size 
(defined by US examination) was high (p=0.002). 
Regarding the homogeneity of regression, the luminal A, HER-2 and triple negative 
breast cancers (TNBCs) showed more homogeneity, whereas luminal B cases demonstrated 
more inhomogeneity. Unfortunately, statistical analysis could not been applied due to the low 
case number in the groups. Lack of any regression, uniform degree of regression and pCR 
were observed in 7.5%, 18.8% and 28.3% of all cases, respectively. The vast majority of 
inhomogeneous regression was minor inhomogeneity (36.7% of all cases). The scatter pattern 
was identified in only 8 cases (7.5%), while CS was the rarest (n=2; 1.8%). The regression 
inhomogeneity is demonstrated in Table 3 displaying the distribution of complete regression 
and the lack of any regression patterns at the different magnifications evaluated. In the lymph 
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node specimens, homogeneity was more frequent (homogeneity: 45.3% versus 
inhomogeneity: 23.5% of all cases). In cases having neither metastasis nor regression in the 
lymph nodes, homogeneity of regression or its lack could not be evaluated (31.2 %). 
Cellularity changes reflected decrease in most cases (two thirds of all patients) but an 
increase was recorded in a significant minority (15.1%). The correlation between changes in 
cellularity and the alterations of post-treatment pathological and radiological tumor sizes 
compared to the pretreatment US size were significant (p=0.04 and p=0.03, respectively). 
After exclusion of cases showing pCR following PST (where grade alteration was not 
interpretable) the grade of tumors was unchanged in 72.4%. Upgrading and downgrading 
were detected in 10 and 10 cases (13.8% and 13.8%), respectively. The latter was not seen 
among patients having TNBC. 
“Monster” cells were seen in 17.9% (n=19) of all cases. They were present in pre- and 
posttreatment grade 2 and 3 tumors exclusively. Their possible influence on grade alteration 
and association with PST are demonstrated in Table 4. Among these findings, the following 
are underlined: in 5 cases, upgrading (grade 2 to post-treatment y-grade 3) was detected in 
presence of “monster” cells and the monster cells were present only (all but one case) in 
patients who received PST including a taxane. 
No correlation was found between the molecular subtypes and treatment related 
alteration in (pathological) size, cellularity, grade, the homogeneity of regression in lymph 
node specimens and presence of "monster" cells. 
 
Discussion 
The concepts of PST were developed in the last years and offer an alternative option 
for patients having primary breast cancer. The aims of PST are combination of systemic 
treatment and surgical treatment in order to eliminate all tumor cells, down staging breast 
cancers to make them operable by breast conserving options, and enabling the assessment of 
regression by pathological means [23-25]. In PST studies, the pathological diagnosis is the 
most important parameter for the generation of study endpoints [26]. The histopathological 
changes after PST are complex, therefore careful systematic analysis of the specimen is 
required for accurate diagnosis and treatment. The standardization of specimen handling and 
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histological interpretation is essential for approaching pCR as an indicator in PST studies, or 
for measuring residual disease [10]. 
Although one of the most cardinal features of residual disease is the tumor size, it is 
often difficult to determine after PST. Besides the hardships of systematic sampling of the 
tumor bed, residual tumor may be present as multiple, small scattered foci. In the latter case, 
the size of the largest invasive focus determines the ypT category according to the 8th edition 
of the AJCC staging system [13], while the extent defined by the largest dimension inclusive 
of all independent invasive foci may be better for comparison with radiologic size [12]. Our 
findings have demonstrated, that pathological tumor size correlates with radiological (US) 
size, and the alteration of pathological size is in keeping with radiological findings [27; 28]. 
Primary chemotherapy selectively eliminates the proliferating cells, therefore the 
mitotic activity and the cellularity may decrease. Though, the change in cellularity is one of 
the most representative features of PST [29], it is not recorded routinely in the 
histopathological reports, because it is not easy to assess, lacks standardization and is an 
important parameter in only some tumor-response systems [16; 30] while it is not one in 
others [31-33]. Cellularity is utilized in two regression grading systems: in the Miller-Payne 
and in the Residual Cancer Burden system (RCB). Regarding the five-tiered Miller-Payne 
system, the pre- and post PST cellularity are compared, and the presence of invasive 
carcinoma is considered [16]. The four-tiered RCB is based on the size of the tumor bed in 
two dimensions, tumor cellularity in the post-treatment specimen, the proportion of DCIS in 
residual cancer, the number of lymph nodes with residual metastasis and the size of the largest 
lymph node metastasis [30]. In the present series, biopsies taken before PST and resection 
specimen were evaluated for cellularity changes. In the vast majority of the cases, cellularity 
has declined and a significant correlation was detected between alterations of cellularity and 
(pathological) size. 
Our findings suggest that homogeneity and inhomogeneity of regression are not 
associated with any molecular subtypes, and both are present approximately in half of the 
cases. The majority of inhomogeneous regression represented minor inhomogeneity seen in 
differences between one and the other medium or low power field, while the scatter pattern 
and CS were exceptionally rare. Although, the most remarkable pattern is the scatter pattern 
regarding the problems of tumor bed sampling (Figure 1 and introductory example), where 
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complete slides may be present without residual cancer, minor heterogeneity may also cause 
diagnostic controversy if only core biopsy is taken after PST. 
Several ongoing or completed studies on PST feature post-PST biopsies as parts of the 
design [34-38]. By taking interim or final biopsies, pathological response and the effects of 
treatment can be characterized. Tumor heterogeneity, especially the scatter pattern of 
regression may have an impact on these studies. Limited sampling by biopsies may be the 
source of misinterpretations, if the biopsy is taken from the part of tumor bed showing 
complete response, or another part lacking any response. To avoid these diagnostic pitfalls, 
generous sampling by multiple biopsies is recommended for cases showing the extremes on 
the scale of regression, if the assessment of the complete tumor bed is not feasible. The results 
may also have an impact on the management of cases similar to the introductory example: an 
empty tumor bed with tumor bed on the inked margin may not be a perfect evidence of pCR 
or complete tumor resection. 
Histological grade of breast cancer is one of the most established traditional prognostic 
factors. Honkoop and coworkers have found significant decline in mitotic activity following 
PST [39], while Sharkey et al have identified significant increase of nuclear pleomorphism 
[40]. While the decline of mitotic count can lead to “downgrading”, more severe nuclear 
atypia could result in “upgrading”. The result of these contradirectional changes may alter the 
posttreatment histological grade. We have demonstrated that up- and downgrading are rare, 
especially because the majority of PST case belong to grade 3. In half of the cases with 
upgrading, monster cells were present. 
The monster cells (Figure 2H-I) are giant tumor cells often having hyperchromatic 
macronuclei or multilobated or multiple nuclei and they are associated with effects of PST 
[40]. The presence of these cells was associated with taxane treatment. The principal effect of 
taxanes is the disruption of microtubule function, including the blockage of the mitotic 
spindle. Microtubules are essential to cell division, and taxanes stabilize GDP-bound tubulin 
in the microtubule, thereby inhibiting the process of cell division as depolymerization is 
prevented. The tumor cells are not able to divide after the duplication of their chromatin 
content, and the result may be the formation of macronucleated “monster” cells. Our findings 
suggest that the presence of these monster cells may increase nuclear atypia and therefore it 
may lead to upgrading following PST. Due to polyploidization, such cells are also expected to 
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show an increased copy number of many genes, including HER2, leading to a post-treatment 
positive status of questionable therapeutic significance in these cells [41]. 
Limitations of the present study could be the low number of cases and the exclusion of 
patients receiving primary hormone therapy (PHT). Fukada and coworkers have reported that 
CS is significantly more frequent in luminal breast cancers following PHT, and these patients 
had significantly better outcome than patients having other patterns [42]. In contrast, there 
was no significant correlation between regression patterns and molecular subtypes in present 
work. This discrepancy may be explained by the exclusion of cases with PHT. 
To our knowledge, this is the first study describing the distribution of regression 
heterogeneity according to molecular subtypes. Our findings suggest that regression may be 
inhomogeneous in half of the cases, and it does not seem to be related to any molecular 
subtype, therefore the evaluation of the whole tumor bed is recommended for the best 
assessment of regression. The “monster” cells are related to PST including taxane derivate, 
and may cause upgrading in tumors with non-high grade nuclei at the start of PST.  
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Figure legends: 
Figure 1. Example case with inhomogeneous (scatter pattern) regression. 
A. Cellular tumor on core needle biopsy (HE, 40x) 
B. Empty tumor bed with remnants of an intraductal papilloma in the firstly excised 
surgical specimen. No margin labeling ink on tumor (free margin?), but ink on the 
empty tumor bed. (HE, 40x) 
C. Second surgical specimen included both areas of empty tumor bed (top right third) and 
residual invasive carcinoma (HE, 40x) 
D.  Higher magnification of part C, with residual invasive tumor cell clusters (HE, 400x) 
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Figure 2. Patterns of regression and peculiar cellular changes (monster cells) in post-treatment 
specimens.  
A. Complete pathological regression (HE,40x) 
B. Absence of any regression in the tumor bed (HE, 40x) 
C. Homogenous regression (HE, 40x) 
D. Concentric shrinkage pattern (HE, 40x) 
E. Inhomogenous regression in a tumor bed. Big red circle and small yellow circle 
display 40x and 100x field area, respectively. (HE, 1x) 
F.  40x field area of tumor bed on “E” slide shows complete response (HE, 40x) 
G. 10x field area of tumor bed on “E” slide lacks any regression (HE, 100x) 
H. and I. bizarre macronucleated “monster” cells (HE, 400x) 
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Table 1. Clinical characteristics of patients. (SLND: sentinel lymph node dissection, ALND: axillary 
lymph node dissection, NST: breast carcinoma of no special type, ypT and ypN: categories defined by 
the 8th edition of Cancer staging manual introduced by AJCC [13:AJCC]) 
Clinical parameters   
Age (year)   
Range 32-77 
mean / median 54.5 / 55 
Type of surgery (n; (%))   
Mastectomy 71 (66.9) 
breast conserving surgery 35 (33.1) 
Type of lymphadenectomy (n; (%))   
SLND 35 (33.1) 
ALND 80 (75.4) 
SLND+ALND 10 (9.4) 
None 1 (0.9) 
Histological type of tumor (n; (%))   
NST 100 (94.5) 
Lobular 4 (3.7) 
Other 2 (1.8) 
ypT (n; (%))   
ypT0 25 (23.6) 
ypTis 5 (4.7) 
ypT1a 8 (7.5) 
ypT1b 9 (8.6) 
ypT1c 18 (16.9) 
ypT2 30 (28.3) 
ypT3 9 (8.6) 
ypT4 2 (1.8) 
ypN (n; (%))   
ypN0 55 (51.8) 
ypN1 26 (24.5) 
ypN2 12 (11.3) 
ypN3 11 (10.3) 
no data 2 (1.8) 
Grade on core needle biopsy (n; (%))   
1 6 (5.6) 
2 41 (38.7) 
3 59 (55.7) 
Treatment (n; (%))   
anthracycline +/- targeted therapy 9 (8.6) 
taxane +/- platinum derivatives 27 (25.4) 
anthracycline + taxane 70 (66.0) 
 Table 2. Morphological features of cases evaluated, displayed according to the molecular subtypes of breast cancer [20] 
  Luminal A Luminal B HER-2 TNBC 
Morphological variable n (%) n (%) n (%) n (%) 
  20 (100) 29 (100) 26 (100) 31 (100) 
Radiological size alteration         
shrinkage 15 (75) 26 (89) 24 (92.4) 25 (80.6) 
growth 2 (10) 0 (0) 2 (7.6) 4 (12.9) 
unchanged 2 (10) 3 (11) 0 (0) 2 (6.5) 
no data 1 (5) 0 (0) 0 (0) 0 (0) 
Regression pattern in the resection specimen         
Homogeneous 14 (70) 10 (34.4) 15 (57.6) 19 (61.3) 
pCR 0 (0) 6 (20.7) 12 (46.2) 12 (38.7) 
uniform degree of regression 11 (55) 3 (10.3) 2 (7.6) 4 (12.9) 
lack of any regression 3 (15) 1 (3.4) 1 (3.8) 3 (9.6) 
Inhomogeneous 6 (30) 19 (65.6) 11 (42.3) 12 (38.7) 
minor inhomogeneity 5 (25) 17 (58.8) 9 (34.7) 8 (25.9) 
"scatter pattern" 1 (5) 2 (6.8) 1 (3.8) 3 (9.6) 
concentric shrinkage 0 (0) 0 (0) 1 (3.8) 1 (3.2) 
Regression pattern in the lymph node specimen         
homogeneous 9 (45) 12 (41.4) 13 (50) 14 (45.2) 
inhomogeneous 7 (35) 10 (34.5) 4 (15.4) 4 (12.9) 
not applicable 4 (20) 7 (24.2) 9 (34.6) 13 (41.9) 
Change in cellularity         
decreased 15 (75) 23 (79.5) 21 (80.8) 22 (70.9) 
increased 2 (10) 3 (10.3) 4 (15.4) 7 (22.6) 
unchanged 3 (15) 1 (3.4) 1 (3.8) 2 (6.5) 
no data 0 (0) 2 (6.8) 0 (0) 0 (0) 
Change in grade         
decreased 4 (20) 3 (10.3) 3 (11.5) 0 (0) 
increased 2 (10) 5 (17.3) 0 (0) 3 (9.6) 
unchanged 14 (70) 12 (41.4) 11 (42.3) 15 (48.3) 
no data 0 (0) 9 (31.0) 12 (46.2) 13 (41.9) 
Presence of “monster” cells         
present 5 (25) 6 (20.6) 3 (11.5) 5 (16.1) 
absent 15 (75) 23 (79.4) 23 (88.4) 26 (83.9) 
(HER-2: human epidermal growth factor receptor-2; TNBC: triple negative breast cancer, pCR: pathological complete regression) 
 Table 3. Morphological characteristics of regression patters 
Patterns of 
inhomogeneity 
  complete regression pattern at magnification of/on lack of any regression pattern at magnification of/on 
n 40x 100x whole slide absent 40x 100x whole slide absent 
minor inhomogeneity 39 19 (48.7) 14 (35.8) 0 6 (15.5) 15 (35.5) 9 (23) 3 (7.8) 12 (30.7) 
scatter pattern 7 0 0 7 (100) 0 2 (28.5) 3 (43) 0 2 (28.5) 
concentric shrinkage 2 2 (100) 0 0 0 0 1 (50) 0 1 (50) 
 
Note: When a pattern was present on the whole slide, it was also present in a medium power (10x) and low power field, too; but the numbers in the table reflect only 
the largest of the three areas assessed.
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Table 4. Relation between alterations of grade, therapy received and “monster” cells, respectively. 
  monster cells 
Alteration of grade present absent 
increased 5 5 
decreased 1 9 
unchanged 11 41 
no data 2 32 
Therapy     
anthracycline +/- targeted therapy 1 8 
taxane +/- platinum derivatives 4 23 
anthracycline + taxane 15 55 
 
